Chiropractors in Hudson, NY Accepting Medicare
8 Chiropractors found. Showing 1 - 8
 Dr. Gary E Lynk, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 322 Fairview Ave, Hudson, NY 12534 Phone: 518-828-3662 Fax: 518-828-3845 |
 Dr. Emily Fair, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 351 Fairview Ave Ste 600, Hudson, NY 12534 Phone: 518-828-3662 |
Michael Pyfrom Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 453 State St, Hudson, NY 12534 Phone: 518-267-9670 Fax: 518-267-9670 |
Dr. William J. Kowalski, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 3920 Us Route 9, Hudson, NY 12534 Phone: 518-822-0060 Fax: 518-822-0061 |
Dr. Julia Wilson, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 64 Green St, Hudson, NY 12534 Phone: 518-828-2133 |
Dr. Sarah M Cihocki, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 968 Columbia St, Hudson, NY 12534 Phone: 518-828-4100 Fax: 518-828-4124 |
Dr. Brandon L Manson, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 351 Fairview Ave, Suite 600, Hudson, NY 12534 Phone: 518-828-3662 Fax: 518-828-3845 |
 Kb Chiropractic Chiropractor Medicare: Medicare Enrolled Practice Location: 322 Fairview Ave, Hudson, NY 12534 Phone: 518-828-3662 Fax: 581-828-3845 |
News Archive
Rice University looks to ‘trap and zap' SARS-CoV-2 in wastewater
A team of researchers from Rice University has won a National Science Foundation (NSF) RAPID grant to adapt their wastewater nanotechnology project to help trap and inactivate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), (which causes COVID-19 disease), in wastewater. This could help public health officials deal with the threat of disease transmission through wastewater.
Florida Senate committee rejects Medicaid expansion
The vote doesn't stop an expansion of coverage to the state's uninsured since the panel could make an alternative recommendation.
Santarus enrolls 510 patients in Phase III clinical program for budesonide MMX
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
FRC applauds FDA for rejecting over-the-counter pill in America's pharmacies
Citing a concern that young teenagers may not safely use the morning after pill without a doctor's guidance, the Food and Drug Administration (FDA) late today officially rejected a plan to make the pill available over-the-counter in America's pharmacies. Family Research Council President Tony Perkins released the following statement in response to the FDA's decision:
› Verified 2 days ago
Physical Therapists
Speech-Language Pathologists
Optometrists
Chiropractors
Occupational Therapists
Podiatrists
Audiologists